Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNAP for Staphylococcus aureus bacteremia
2023-503582-35-00Phase 4Authorised
- Sponsor
- University Medical Center Utrecht
- Start
- Oct 2023
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 4
01
Overview
Phase 4, randomised, open-label trial of flucloxacillin, Benzathine penicillin, daptomycin, doxycycline, moxifloxacin and 9 more in Staphylococcal bacteremia, sponsored by University Medical Center Utrecht. Primary endpoint: All-cause mortality at 90 days. Planned start Oct 2023; status: authorised.
02
Drugs
flucloxacillinBenzathine penicillindaptomycindoxycyclinemoxifloxacin
03
Conditions
Staphylococcal bacteremia
Beyond the preview
Go deeper on 2023-503582-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503582-35-00.